Table 1 pCR by adding Oxaliplatin to 5-FU for rectal cancer
Trial | N | Regimen | pCR rate |
|---|---|---|---|
STAR-01 | 705 | 5-FU vs. 5-FU + Oxaliplatin | 16% vs. 16% (p = 0.904) |
ACCORD 12 | 598 | Capecitabine vs. CAPOX | 13.9% vs. 19.2% (p = 0.09) |
NSABP R-04 | 1608 | 5-FU vs. 5-FU + Oxaliplatin vs. Capecitabine vs. CAPOX | 17.8% vs. 19.5% (p = 0.42) |
CAO/ARO/AIO-04 | 1236 | 5-FU vs. 5-FU + Oxaliplatin | 13% vs. 17% (p = 0.031) |
PETACC-6 | 1094 | Capecitabine vs. CAPOX | 11.3% vs. 13.3% (p = 0.31) |
Dellas et al. | 70 | CAPOX + Bevacizumab | 17.4% |
EXPERT-C | 165 | CAPOX vs CAPOX + Cetuximab | 7% vs. 11% (p = 0.714) |